Welcome to our dedicated page for Daxor Corporation news (Ticker: DXR), a resource for investors and traders seeking the latest updates and insights on Daxor Corporation stock.
Daxor Corporation Common Stock (DXR) represents a pioneering medical instrumentation and biotechnology company focused on the accurate measurement of blood volume. Daxor develops and markets the BVA-100 (Blood Volume Analyzer), which stands as the first FDA-cleared diagnostic tool capable of providing precise, objective quantification of blood volume status and composition compared to patient-specific norms. This technology is pivotal across a wide range of medical conditions.
The BVA-100 has revolutionized blood volume measurement, a practice that has historically been prone to lengthy and inaccurate testing processes. Traditional methods often took 4 to 8 hours and yielded inconsistent results. In contrast, the BVA-100 can deliver accurate and reliable measurements quickly, enhancing the capabilities of physicians who previously had to rely on less precise tests that measured blood thickness, often leading to misleading outcomes in critical medical situations.
Daxor Corporation, headquartered in New York, is at the forefront of medical technology and innovation. The company's recent achievements include the development of the next generation of Blood Volume Analyzer Systems, securing further research patents, and producing excellent clinical outcomes. These advancements are not only enhancing the quality of patient care but also strengthening the company's market position.
Financially, Daxor has shown robust growth, with unaudited revenue climbing 229.1% in the first two months of 2024 year-on-year. The company's strong start to 2024 is indicative of its commitment to innovation and excellence. Daxor is also actively engaged in strategic partnerships and investor relations, with Bret Shapiro serving as the Senior Managing Partner at CORE IR, ensuring transparent and effective communication with investors and stakeholders.
In addition to its technological developments, Daxor is also a notable presence in the medical community, participating in significant events such as the Premier Event for Cardiovascular Industry Leaders and Clinicians. The company's research and publications, such as those presented at the American College of Cardiology Scientific Sessions and in the American Heart Journal, underscore its dedication to advancing medical knowledge and practice.
Daxor Corporation (Nasdaq: DXR) will present new patient outcome data at the Annual Scientific Meeting of the Heart Failure Society of America from September 30 to October 3, 2022, in Washington, DC. Key findings include significant reductions in heart failure readmissions (56%), 30-day mortality (82%), and 1-year mortality (86%) associated with blood volume analysis (BVA). This event will gather leading experts to discuss advancements in heart failure management. Daxor aims to improve healthcare through BVA technology, which has been validated by over 60,000 tests nationwide.
Daxor Corporation (Nasdaq: DXR) announces CEO Michael Feldschuh's participation at the H.C. Wainwright 24th Annual Global Investment Conference, scheduled for September 12-14, 2022, in New York. Attendees can request one-on-one meetings with him through the provided registration link. Daxor is renowned for its blood volume measurement technology, particularly the BVA-100®, enabling accurate quantification of blood volume, significantly improving patient outcomes. The company is involved in ongoing trials supported by the NIH, focusing on COVID-19 and heart failure treatment.
Daxor Corporation (Nasdaq: DXR), a leader in blood volume measurement technology, reported a 35.3% increase in net assets, totaling $19.6 million or $4.85 per share as of June 30, 2022. Despite a 7.3% decrease from year-end 2021, the operating division's valuation remained stable at $16.5 million. The company experienced a 92.6% revenue increase in its diagnostic segment, driven by sales and leasing of equipment. Furthermore, Daxor successfully completed a DOD contract for a portable blood volume analyzer, with anticipated FDA approval by Q4 2022, paving the way for a significant product launch.
Daxor Corporation (NYSE: DXR) reported a remarkable 92.6% revenue growth driven by the successful commercialization of its BVA-100® Blood Volume Analyzer. Significant factors include the launch of 12 new accounts, a 9.2% price increase, and orders from the U.S. Department of Defense. The firm also disclosed net assets of $19.6 million per share, rising 35.3% year-over-year. Furthermore, Daxor is progressing on a new portable blood volume analyzer with FDA submission expected by year-end, projecting a 2023 launch.
Daxor Corporation (Nasdaq: DXR) will announce its financial results for the six months ending June 30, 2022, on August 25, 2022, at approximately 4:00 p.m. ET. The earnings conference call will be hosted by President and CEO Michael Feldschuh and CFO Robert Michel at 4:30 p.m. ET on the same day. Investors can participate in a Q&A session by submitting their questions via email. The conference call will also be available through a live webcast, with replay options until November 25, 2022. Daxor is recognized for its innovative blood volume measurement technologies.
Daxor Corporation (Nasdaq: DXR) reported a 49.4% increase in year-over-year sales of its single-use diagnostic kits. The company also achieved a 10.4% growth in sales from Q1 to Q2 2022, benefitting from new accounts and increased capital equipment purchases. Recent successes include a major acquisition at a leading Illinois academic center and expansion within a major South Carolina healthcare organization servicing 1.5 million patients. Ongoing clinical studies and contracts with the U.S. military are not included in these figures but are contributing additional revenue.
Daxor (Nasdaq: DXR) has partnered with MedAxiom to enhance the adoption of its blood volume analysis (BVA) technology. This collaboration aims to improve patient outcomes, reduce healthcare costs, and optimize clinician experiences as heart failure diagnoses rise. Daxor's BVA technology has demonstrated significant improvements in patient metrics, including an 82% decrease in 30-day mortality and enhanced treatment plans with 98% accuracy. The partnership leverages MedAxiom's extensive network to accelerate technology delivery in the cardiovascular community, aligning with healthcare’s Quadruple Aim.
Daxor Corporation (Nasdaq: DXR) has secured funding from the National Institute of Health (NIH) to enhance its clinical decision support software aimed at improving heart failure treatment.
The company participated in the NIH's Innovation Corps (I-Corps™) program, which supports businesses ready for commercialization of NIH-funded projects. This program provided vital resources to accelerate the launch of Daxor’s software, designed to optimize fluid management in acute heart failure.
Daxor Corporation (Nasdaq: DXR) has entered a Cooperative Research and Development Agreement with The Uniformed Services University and The Henry M. Jackson Foundation. The collaboration aims to develop a non-nuclear blood volume diagnostic device, enhancing the existing BVA-100 technology. This device is designed for both military and civilian use, targeting conditions like trauma and heart failure. Extensive studies validate Daxor's technology, showing a potential for improved patient outcomes by significantly enhancing fluid management in critical care.
Daxor Corporation (Nasdaq: DXR), a leader in blood volume measurement technology, will exhibit at the American Association of Heart Failure Nurses 18th Annual Meeting from June 15-18, 2022, in Orlando, Florida. They aim to educate healthcare professionals on their blood volume technology, which reportedly reduces 30-day mortality by 82% and readmissions by 56%. Daxor has conducted over 60,000 tests across the U.S., contributing to better patient outcomes in various medical conditions, including heart failure.
FAQ
What is the current stock price of Daxor Corporation (DXR)?
What is the market cap of Daxor Corporation (DXR)?
What does Daxor Corporation specialize in?
What is the BVA-100?
How has the BVA-100 improved blood volume measurement?
What are some recent achievements of Daxor Corporation?
How has Daxor performed financially in early 2024?
Who is the Investor Relations Contact at Daxor Corporation?
What kind of medical events does Daxor participate in?
Where has Daxor Corporation published its research findings?
What is the significance of the BVA-100 in medical practice?
Where is Daxor Corporation headquartered?
